Table 4

Reason for Sertindole Discontinuation during Study Follow-up (682 patients), with type of previously taken treatment


Total N (%)

Reason for Stopping
Beforea
Afterb

Sertindole suspension and Named Patient Use restrictions
176 (35.3%)
49 (26.8%)
Typical antipsychotic(s)c
50 (25.1%)
28 (31.5%)
At least one atypical antipsychoticd
49 (31.6%)
15 (20.8%)

Patient desire to stop
127 (25.5%)
50 (27.3%)
Typical antipsychotic(s)c
71 (35.7%)
26 (29.2%)
At least one atypical antipsychoticd
39 (25.2%)
18 (25.0%)

Lack of efficacy
64 (12.8%)
39 (21.3%)
Typical antipsychotic(s)c
28 (14.1%)
17 (19.1%)
At least one atypical antipsychoticd
23 (14.8%)
19 (26.4%)

Adverse Event(s)
58 (11.6%)
19 (10.4%)
Typical antipsychotic(s)c
26 (13.1%)
10 (11.2%)
At least one atypical antipsychoticd
20 (12.9%)
9 (12.5%)

Other reasons
74 (14.8%)
26 (14.2%)
Typical antipsychotic(s)c
24 (12.1%)
8 (9.0%) 11
At least one atypical antipsychoticd
24 (15.5%)
(15.3%)

Total
499 (100.0%)
183 (100.0%)

a For 2 patients, reason for stopping sertindole treatment was missing.

b For 1 patient, reason for stopping sertindole treatment was missing.

c For 129 patients, the name of the antipsychotic given before sertindole treatment was missing and 48 patients had no antipsychotic treatment before sertindole.

d For 8 patients, the name of the antipsychotic given before sertindole treatment was missing and 25 patients had no antipsychotic treatment before sertindole.

Lançon et al. BMC Psychiatry 2008 8:57   doi:10.1186/1471-244X-8-57